DIA3 Antibody

What is DIAPH3 protein and what cellular functions does it perform?

DIAPH3 is an actin nucleation and elongation factor required for the assembly of F-actin structures, such as actin cables and stress fibers. Located primarily in the cytoplasm and at the cell membrane, DIAPH3 is essential for actin polymerization, which is critical for maintaining cell shape, motility, and division. It plays vital roles in cytokinesis, stress fiber formation, and transcriptional activation of the serum response factor. DIAPH3 interacts with Profilin, a key regulator of actin filament assembly, and the GTP-bound form of Rho (Rho-GTP), facilitating the recruitment of Profilin to the membrane in a Rho-dependent manner .

Additionally, DIAPH3 acts as an actin nucleation and elongation factor in the nucleus by promoting nuclear actin polymerization to drive serum-dependent SRF-MRTFA activity. DFR proteins, including DIAPH3, couple Rho and Src tyrosine kinase during signaling and the regulation of actin dynamics .

What types of DIAPH3 antibodies are available for research applications?

There are multiple types of DIAPH3 antibodies available for research applications, primarily:

• Mouse monoclonal antibodies: Such as the DIAPH3 Antibody (4D5), which is an IgG2a κ mouse monoclonal antibody that detects human DIAPH3 in various applications .

• Rabbit polyclonal antibodies: Such as the rabbit polyclonal DIAPH3 antibody suitable for Western blot and reacting with human samples .

Each antibody type has distinct advantages. Monoclonal antibodies offer high specificity for a single epitope, ensuring consistent results across experiments. Polyclonal antibodies recognize multiple epitopes on the antigen, potentially providing stronger signals by binding to several sites on the target protein.

What applications are DIAPH3 antibodies validated for?

DIAPH3 antibodies have been validated for multiple research applications as shown in the following table:

When selecting a DIAPH3 antibody, researchers should consider which applications they plan to use and verify that the specific antibody has been validated for those techniques .

How can I optimize Western blot conditions for DIAPH3 detection?

Optimizing Western blot conditions for DIAPH3 detection requires careful consideration of several factors:

• Sample preparation: Given DIAPH3's molecular weight of approximately 137 kDa, use appropriate gel concentrations (typically 7-10% polyacrylamide) for optimal separation.

• Loading control selection: Choose loading controls that do not overlap with the DIAPH3 band (137 kDa).

• Antibody concentration: Start with the manufacturer's recommended dilution. For example, some DIAPH3 antibodies have been shown to work well at 1 μg/mL for Western blotting .

• Predicted band size: Verify band size against the predicted molecular weight (137 kDa) to ensure specificity .

• Protein expression verification: Consider using DIAPH3-transfected cell lysates as positive controls alongside non-transfected lysates as negative controls to confirm antibody specificity .

When troubleshooting, remember that DIAPH3 has seven distinct isoforms resulting from alternative splicing, which may appear as multiple bands on your Western blot .

What controls should I include when using DIAPH3 antibodies for experimental validation?

Proper controls are essential for validating DIAPH3 antibody results:

• Positive controls:

  • DIAPH3-transfected cell lysates, as demonstrated in published Western blots where DIAPH3-transfected 293T cell lysates showed specific bands compared to non-transfected controls .

  • Cell lines known to express high levels of DIAPH3.

• Negative controls:

  • Non-transfected cell lysates .

  • Isotype controls (antibodies of the same isotype but not targeting DIAPH3).

  • Secondary antibody-only controls to identify non-specific binding.

• Knockdown/knockout validation:

  • DIAPH3 siRNA or shRNA-treated samples.

  • CRISPR/Cas9-mediated DIAPH3 knockout cells.

• Peptide competition assays to confirm antibody specificity by pre-incubating the antibody with excess target peptide.

These controls help ensure that any observed signals are specific to DIAPH3 and not due to non-specific binding or experimental artifacts.

How can I use DIAPH3 antibodies to investigate its interaction with Rho GTPases?

To investigate DIAPH3's interaction with Rho GTPases, consider these methodological approaches:

• Co-immunoprecipitation (Co-IP):

  • Use DIAPH3 antibodies to pull down DIAPH3 and probe for co-precipitated Rho GTPases.

  • Alternatively, use Rho GTPase antibodies for pulldown and probe for DIAPH3.

  • Include GTPγS (non-hydrolyzable GTP analog) in some reactions to lock Rho in its active state.

• Proximity ligation assay (PLA):

  • Use DIAPH3 and Rho antibodies from different species to visualize endogenous protein interactions in situ.

• Immunofluorescence co-localization:

  • Use DIAPH3 antibodies alongside Rho GTPase staining to examine spatial co-localization, particularly at the cell membrane where DIAPH3 is recruited in a Rho-dependent manner .

• GST pulldown assays:

  • Use GST-tagged Rho GTPases (loaded with GTP or GDP) to pull down endogenous DIAPH3, then detect with DIAPH3 antibodies.

When interpreting results, remember that DIAPH3's activity is regulated through its diaphanous autoregulatory domain (DAD) and Rho GTPase-binding domain (GBD); when these domains are bound intramolecularly, DIAPH3 remains inactive. Disruption of this bond allows the GBD to engage with Rho-GTP, thus activating DIAPH3 .

What factors should be considered when using DIAPH3 antibodies for immunofluorescence studies?

When designing immunofluorescence experiments with DIAPH3 antibodies, consider:

• Fixation method:

  • Paraformaldehyde (4%) preserves cell morphology and cytoskeletal structures.

  • Methanol fixation may be preferable for certain epitopes but can disrupt some actin structures.

• Permeabilization:

  • Use 0.1-0.3% Triton X-100 for cytoplasmic access while preserving actin structures.

  • Avoid overly harsh detergents that might disrupt the cytoskeleton.

• Blocking parameters:

  • Longer blocking times (1-2 hours) may reduce background.

  • BSA (3-5%) or normal serum (5-10%) from the species of the secondary antibody.

• Co-staining considerations:

  • Pair DIAPH3 antibody with phalloidin to visualize F-actin structures.

  • Consider co-staining with Rho GTPases or Profilin to examine co-localization.

• Subcellular localization expectations:

  • DIAPH3 is primarily located in the cytoplasm and at the cell membrane .

  • Look for enrichment at stress fibers, cell division structures, and membrane protrusions.

Remember that DIAPH3 association with different cellular structures may vary depending on cell type, cell cycle stage, and activation state of signaling pathways.

How can I validate the specificity of DIAPH3 antibodies in my experimental system?

Validating DIAPH3 antibody specificity requires a multi-faceted approach:

• Genetic validation:

  • siRNA or shRNA knockdown: Compare staining/signal between knockdown and control samples.

  • CRISPR/Cas9 knockout: Use as a definitive negative control.

  • Overexpression: Analyze increased signal in DIAPH3-overexpressing cells.

• Biochemical validation:

  • Peptide competition: Pre-incubate antibody with immunizing peptide to block specific binding.

  • Multiple antibodies: Use antibodies targeting different DIAPH3 epitopes and compare results.

  • Immunoprecipitation followed by mass spectrometry to confirm target identity.

• Size verification in Western blotting:

  • Verify that the observed band matches the predicted molecular weight (137 kDa) .

  • Account for potential post-translational modifications or splice variants.

• Cross-reactivity assessment:

  • Test antibody on samples from multiple species if working with non-human models.

  • Consider potential cross-reactivity with related formins (DIAPH1, DIAPH2).

Proper validation ensures experimental results are genuinely reflective of DIAPH3 biology rather than artifacts.

How can DIAPH3 antibodies be used to study nuclear actin dynamics?

DIAPH3 plays a role in nuclear actin polymerization, driving serum-dependent SRF-MRTFA activity . To study this function:

• Nuclear-cytoplasmic fractionation:

  • Use DIAPH3 antibodies to detect and quantify DIAPH3 levels in nuclear vs. cytoplasmic fractions.

  • Compare fractionation patterns under different stimulation conditions.

• Chromatin immunoprecipitation (ChIP):

  • Use DIAPH3 antibodies to isolate chromatin-associated DIAPH3.

  • Pair with SRF or MRTFA antibodies to study co-occupancy at target gene promoters.

• Advanced microscopy approaches:

  • Super-resolution microscopy with DIAPH3 antibodies to visualize nuclear actin structures.

  • FRAP (Fluorescence Recovery After Photobleaching) with fluorescently-tagged DIAPH3 to study dynamics.

  • Live-cell imaging using anti-DIAPH3 nanobodies.

• Nuclear actin polymerization assays:

  • In vitro assays using purified nuclear extracts and DIAPH3 antibodies for immunodepletion.

  • Pyrene-actin polymerization assays in the presence and absence of immunoprecipitated DIAPH3.

When designing these experiments, consider the regulatory mechanisms that might control DIAPH3's nuclear localization and activity, including post-translational modifications and protein-protein interactions.

What are the considerations for using DIAPH3 antibodies in cancer research studies?

When studying DIAPH3 in cancer contexts, consider:

• Expression level analysis:

  • Use DIAPH3 antibodies for immunohistochemistry on tissue microarrays to evaluate expression across tumor types and grades.

  • Quantify DIAPH3 levels in tumor vs. normal tissues by Western blot.

• Subcellular localization changes:

  • Compare DIAPH3 localization patterns between normal and cancer cells using immunofluorescence.

  • Examine redistribution during epithelial-mesenchymal transition (EMT).

• Interaction with cancer-related pathways:

  • Investigate DIAPH3 interaction with Rho family GTPases, which are frequently dysregulated in cancer.

  • Study DIAPH3's relationship with Src kinases, which are important in oncogenic signaling .

• Migration and invasion assays:

  • Use DIAPH3 antibodies to correlate expression/localization with migratory and invasive phenotypes.

  • Perform immunofluorescence on cells at migration fronts to study DIAPH3 distribution.

• Drug response studies:

  • Examine changes in DIAPH3 expression/localization following treatment with cytoskeletal-targeting agents.

  • Correlate DIAPH3 levels with sensitivity to specific therapeutic agents.

Current research indicates that cytoskeletal regulators like DIAPH3 may play important roles in cancer cell migration, invasion, and metastasis, making this an important area for investigation.

How do I troubleshoot non-specific binding or high background when using DIAPH3 antibodies?

When experiencing non-specific binding or high background:

• Antibody concentration optimization:

  • Perform titration experiments to determine optimal concentration.

  • For Western blotting, try concentrations lower than 1 μg/mL if background is high .

• Blocking optimization:

  • Test different blocking agents (BSA, milk, normal serum, commercial blockers).

  • Increase blocking time or concentration.

• Washing stringency adjustment:

  • Increase number of washes.

  • Add low concentrations of detergents (0.05-0.1% Tween-20) to wash buffers.

• Sample preparation refinement:

  • Ensure complete cell lysis and proper protein denaturation for Western blotting.

  • For tissue sections, optimize antigen retrieval methods.

• Secondary antibody controls:

  • Run controls with secondary antibody only to identify non-specific binding.

  • Consider using directly conjugated primary antibodies to eliminate secondary antibody issues.

• Cross-adsorption:

  • Pre-adsorb antibodies against proteins from the same species as your sample.

If problems persist after optimization, consider alternative DIAPH3 antibodies that target different epitopes, as some regions may be more accessible or specific in your experimental system.

How can I quantitatively assess DIAPH3 expression levels in research samples?

For quantitative assessment of DIAPH3 expression:

• Western blot quantification:

  • Use proper loading controls appropriate for your experimental conditions.

  • Employ digital image analysis software for densitometry.

  • Create standard curves using recombinant DIAPH3 or DIAPH3-overexpressing lysates.

• ELISA development:

  • Use DIAPH3 antibodies validated for ELISA applications .

  • Develop sandwich ELISA using two antibodies targeting different DIAPH3 epitopes.

  • Include standard curves with recombinant DIAPH3 protein.

• Flow cytometry:

  • Optimize fixation and permeabilization for intracellular DIAPH3 staining.

  • Use median fluorescence intensity (MFI) for quantitative comparisons.

  • Include calibration beads to standardize measurements across experiments.

• Quantitative microscopy:

  • Use consistent exposure settings and calibration standards.

  • Perform Z-stack imaging to capture total cellular DIAPH3.

  • Employ automated image analysis for unbiased quantification.

• qPCR correlation:

  • Correlate protein levels detected by antibodies with mRNA expression.

  • Consider potential discrepancies due to post-transcriptional regulation.

For all quantitative applications, include appropriate negative controls and consider the dynamic range of your detection method to ensure measurements fall within the linear range of detection.